32 studies found for:    acorda
Show Display Options
Rank Status Study
1 Completed Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
Condition: Multiple Sclerosis
Intervention: Drug: BIIB041 (Fampridine-SR)
2 Completed
Has Results
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR
3 Completed
Has Results
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR b.i.d. (Twice Daily)
4 Completed
Has Results
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
Conditions: Spinal Cord Injury;   Muscle Spasticity
Interventions: Drug: Fampridine-SR;   Other: Placebo
5 Completed
Has Results
A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Condition: Ischemic Stroke
Interventions: Drug: placebo/dalfampridine-ER;   Drug: dalfampridine-ER/placebo
6 Completed
Has Results
Study of Oral Fampridine-SR in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Fampridine-SR;   Drug: Placebo
7 Completed
Has Results
Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury
Conditions: Spinal Cord Injury;   Muscle Spasticity
Interventions: Drug: Fampridine-SR;   Drug: Placebo
8 Terminated
Has Results
Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
Condition: Spasticity Due to Cerebral Palsy
Intervention: Drug: Zanaflex Capsules
9 Completed
Has Results
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
Condition: Cerebral Palsy (CP)
Interventions: Drug: dalfampridine-ER 10mg;   Other: Placebo
10 Completed
Has Results
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Interventions: Drug: Fampridine-SR;   Drug: Placebo
11 Completed
Has Results
Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment
Condition: Renal Insufficiency
Intervention: Drug: Dalfampridine-ER
12 Active, not recruiting An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: rHIgM22
13 Completed
Has Results
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Dalfampridine-ER 5mg;   Drug: Dalfampridine-ER 10mg;   Other: Placebo
14 Completed A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
Condition: Spasticity
Interventions: Drug: Tizanidine;   Drug: Placebo crossover to moxifloxacin;   Drug: Moxifloxacin crossover to placebo
15 Recruiting A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure
Condition: Heart Failure
Interventions: Other: Placebo;   Drug: GGF2;   Drug: Midazolam
16 Enrolling by invitation A Study of AC105 in Patients With Acute Traumatic Spinal Cord Injury
Condition: Acute Spinal Cord Injury
Interventions: Drug: AC105;   Other: Placebo
17 Completed
Has Results
Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
Condition: Heart Failure
Interventions: Drug: Glial growth factor 2/ Neuregulin 1β3;   Other: Placebo
18 Completed
Has Results
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR
19 Completed
Has Results
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP);   Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP);   Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP)
20 Completed
Has Results
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Other: Withdrawal of dalfampridine-ER 10mg

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
Indicates status has not been verified in more than two years